Clinical Trial Enzyme Application Targeting Venous Leg Ulcers

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

August 9, 2021

Primary Completion Date

February 6, 2023

Study Completion Date

February 6, 2023

Conditions
Venous Leg UlcerLeg Injuries and Disorders
Interventions
DRUG

Aurase Wound gel

Aurase Wound Gel is reconstituted from Aurase Component A (a hydrogel) and Aurase Component B (stabilised solutions of Aurase enzyme). By diluting different strengths of Aurase Component B with Component A, specific concentrations of Aurase Wound Gels with differing Aurase contents are yielded.

Trial Locations (8)

1036

Óbudai Egészségügyi Centrum Kft., Budapest

24153

FASMA, Salem

32224

Mayo Clinic Jacksonville, Jacksonville

33143

Doctors Research Network, Miami

33146

University of Miami, Miami

94117

Center for Clinical Research, San Francisco

Unknown

Uno Medical Trials, Budapest

HU32JZ

Hull Royal Infirmary, Hull

All Listed Sponsors
lead

SolasCure Limited

INDUSTRY

NCT04956900 - Clinical Trial Enzyme Application Targeting Venous Leg Ulcers | Biotech Hunter | Biotech Hunter